Abstract:Background: Hepatitis B virus (HBV) infection is a significant global problem. The main therapies for chronic hepatitis B are nucleos(t)ide analogues (NAs) and (pegylated) interferon (IFN). However, the prognosis of chronic hepatitis B is still not so optimistic since the low serological conversion rate and the high recurrence rate after drug withdrawal.Objectives: This aim was to evaluate the killing activity of cytotoxic T lymphocytes (CTLs) induced by dendritic cells transduced recombinant adenovirus associated virus (rAAV) with different hepatitis B virus gene fragment (HBV-S, C, E, X).Methods: Peripheral blood mononuclear cells (PBMCs) were extracted from chronic hepatitis B patients, and the adhered cells were harvested to cultivate with recombinant adeno-associated virus with different hepatitis B virus (HBV) antigen gene fragment (rAAV-HBV-S, C, E, X) for 7 days by adding GM-CSF, IL-4 and TNF-alpha to generate mature dendritic cells (DCs). The DCs' state were observed and their differentiation antigen molecules (CD) were detected by flow cytometry (FACS) to evaluate their maturation and function. DCs were co-cultured with prepared T lymphocytes to induce cytotoxic T lymphocytes (CTLs). The activity of CTLs induced by different DCs were compared by detection of lymphocyte CD molecules and cytokine levels. HepaG2.2.15 cells were target cells and HepaG2 cells as control. The specific killing activity of CTLs were compared by cell killing assay using 3-(4, 5-dimethylthiazol-2yl)- 5(3-carboxymethoxyphenyl)-2-(4-sulfopheny)-2H-tetrazolium (MTS).Results: The expression of phenotype CD14, CD80, CD83, CD86 from DCs transduced with rAAV-HBV-S, C, E, X and the secretion of cytokine IL-10, IL-12 were compared, respectively. CD80 in rAAV-HBV-S was the highest (P < 0.05), and CD83 in rAAV-HBV-X was the highest (P< 0.05), but other results were not significantly different (P > 0.05). The response of cytotoxic T-lymphocytes induced by different adeno-associated virus (AAV) vector delivery into dendritic cells had significant differences. In comparing the four antigens in terms of CD4+ CD25+ T cells, it was found that rAAV HBV-E group was the highest, and rAAV HBV-X group was the lowest (P < 0.05); CD8+ CD69 + T cells in rAAV HBV-X group was the highest, and rAAV HBV-S group was the lowest (P < 0.05); IFN-gamma levels secreted by CTLs in rAAV HBV-X group was the highest, and rAAV HBV-S group was the lowest (P < 0.05). The specific cell killing activity of CTLs induced by DCs transduced by rAAV-HBV-X to the HepaG2.2.15 cells was the highest, but the four groups were no significant difference, respectively (P > 0.05).Conclusions: These data suggest that rAAV-HBV-S, C, E, Xdelivery into DC may be all useful for immunotherapeutic strategies against hepatitis B virus infection and that the HBV X antigen gene may be the most useful.

Influence of E3 Region on Conditionally Replicative Adenovirus Mediated Cytotoxicity in Hepatocellular Carcinoma Cells

E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.

Effective Inhibition Of Cancer Cells By Recombinant Adenovirus Expressing Egfr-Targeting Artificial Microrna And Reversed-Caspase-3

A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma

Adenovirus-mediated Tissue-Specific Cytosine Deaminase Gene Therapy for Human Hepatocellular Carcinoma with Different AFP Expression Levels.

Enhanced TRAIL sensitivity by E1A expression in human cancer and normal cell lines: inhibition by adenovirus E1B19K and E3 proteins.

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells

Oncolytic Adenovirus-Mediated E1A Gene Therapy Induces Tumor-Cell Apoptosis and Reduces Tumor Angiogenesis Leading to Inhibition of Hepatocellular Carcinoma Growth in Animal Model

Combined Use of Chemotherapeutics and Oncolytic Adenovirus in Treatment of AFP-expressing Hepatocellular Carcinoma

Effect of Cytotoxic T Lymphocytes Induced by Recombinant Adeno-Associated Virus on Different Hepatitis B Virus Genes

Antitumor Effects of Oncolytic Adenovirus-Carrying siRNA Targeting Potential Oncogene EphA3

Inhibitory Effect of Recombinant Adenovirus Carrying Immunocaspase-3 on Hepatocellular Carcinoma

Potent Antitumor Activity Generated by a Novel Tumor Specific Cytotoxic T Cell.

Conditionally Replicating Adenovirus Combined with Gene-Targeted Radiotherapy Induces Apoptosis Via TRAIL Death Receptors in MDA-MB-231 Cells

Improvement of the Cytotoxic T Lymphocyte Response Against Hepatocellular Carcinoma by Transduction of Cancer Cells with an Adeno-Associated Virus Carrying the Interferon-Γ Gene.

Construction and Application of Conditionally Replicative Adenovirus for Selective Cytotoxicity in CEA Positive Colorectal Cancer Cells

Dissecting the Roles of E1A and E1B in Adenoviral Replication and RCAd-enhanced RDAd Transduction Efficacy on Tumor Cells.

[Expression of TRAIL(114-281) Mediated by Adeno-Associated Virus and Its Tumoricidal Activity].